Peer-reviewed article
Active Post-marketing Safety Surveillance of Nirsevimab Administered to Children in Western Australia, April–July 2024
Dale Carcione, Phoebe Spencer, Grace Pettigrew, Alan Leeb, Carla Drake-Brockman et al. ·
Summary
Written by AI, not yet AICS's view ·Key points
Limitations
Abstract
Children receiving nirsevimab were texted a link to an online survey to monitor adverse events following immunization. Total of 4340 parents received the link, which 1195 (27.5%) responded. Forty-seven (11.4%) of 410 children who received nirsevimab alone and 230 (29.3%) of 785 children who received nirsevimab coadministered reported any reaction. No adverse events required in-patient care or had ongoing sequelae.